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Open access unda b s t r a c t
Ethnopharmacological relevance: Piper aleyreanum is a small tree that is widely distributed in tropical
and subtropical regions, mostly in North and South America, and is used as an immunomodulator,
analgesic and antidepressant in folk medicine.
Aim of the study: This study was designed to investigate the antinociceptive, anti-inﬂammatory and
gastric antiulcer activities of the essential oils from the aerial parts of Piper aleyreanum (EOPa) in rodents.
Materials and methods: The antinociceptive and anti-inﬂammatory effects of orally administered EOPa were
evaluated in mice subjected to the formalin and pleurisy models, respectively. We also pretreated the rats
with EOPa before acute ethanol-induced gastric lesions andmeasured gastric lesion extension andmucus and
glutathione (GSH) levels in the gastric mucosa. Finally, we performed a phytochemical analysis of EOPa.
Results: The chemical composition of EOPa was analyzed by gas chromatography and mass spectrometry
(GC/MS), which identiﬁed 35 compounds, representing 81.7% of total oil compounds. Caryophyllene oxide
(11.5%), b-pinene (9%), spathulenol (6.7%), camphene (5.2%), b-elemene (4.7%), myrtenal (4.2%), verbenone
(3.3%) and pinocarvone (3.1%) were the major oil constituents. The oral administration of EOPa
(10–1000 mg/kg) signiﬁcantly inhibited the neurogenic and inﬂammatory phases of formalin-induced licking,
with ID50 values of 281.2 and 70.5 mg/kg, respectively. The antinociception caused by EOPa (100 mg/kg,
p.o.) was not reversed by naloxone (1 or 5 mg/kg, i.p.) in the formalin test. EOPa (100–300mg/kg, p.o.) did
not affect animal motor coordination in an open-ﬁeld model. In carrageenan-induced pleurisy, EOPa
(1–100 mg/kg, p.o.) signiﬁcantly decreased the total cell count, neutrophils and mononuclear cells with
mean ID50 values of 53.6, 21.7 and 43.5 mg/kg, respectively. In addition, EOPa (1–30mg/kg, p.o.) protected
the rats against ethanol-induced gastric lesions with an ID50 value of 1.7 mg/kg and increased the mucus and
GSH levels of the gastric mucosa to levels similar to those of the non-lesioned group.
Conclusions: These data show for the ﬁrst time that EOPa has signiﬁcant antinociceptive and anti-
inﬂammatory actions, which do not appear to be related to the opioid system. EOPa also has interesting
gastroprotective effects related to the maintenance of protective factors, such as mucus production and GSH.
These results support the widespread use of Piper aleyreanum in popular medicine and demonstrate that this
plant has therapeutic potential for the development of phytomedicines with antinociceptive, anti-inﬂam-
matory and gastroprotective properties.
& 2012 Elsevier Ireland Ltd. Open access under the Elsevier OA license.aerial parts of Piper aleyreanum; GSH, glutathione; GC/MS, gas chromatography and mass spectrometry; ASA,
ethacin; SEM, standard error of mean; ANOVA, analysis of variance; NSAIDs, nonsteroidal anti-inﬂammatory drugs;
PGE2, prostaglandin E2; NP-SH, non-protein sulfhydryl groups; ICAM-1, intercellular adhesion molecule-1; VCAM-1,
rotein; DMSO, dimethyl sulfoxide
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Inﬂammation is a basic reaction to infection, irritation or other
injury and is recognized as a type of nonspeciﬁc immune response
that protects the host against injury and initiates speciﬁc immunity
responses. The cardinal signs of inﬂammation can be clinically
characterized as redness, warmth, swelling, loss of function
and pain (Sherwood and Toliver-Kinsky, 2004). Redness and
warmth result from increased blood ﬂow, swelling is associated
with increased vascular permeability, and pain is the conse-
quence of the activation and sensitization of primary afferent
nerve ﬁbers (Lawrence et al., 2002; Sherwood and Toliver-Kinsky,
2004). Therefore, due to their implication in virtually all human
and animal diseases, inﬂammation and pain have become the
focus of global scientiﬁc research.
The drugs most often used for inﬂammation and pain relief in
humans are nonsteroidal anti-inﬂammatory drugs (NSAIDs) and
opioids, despite its well-known adverse effects (Shu, 1998;
Steinmeyer, 2005; Wallace, 2008). Safer, more effective anti-
inﬂammatory and analgesic drugs are urgently needed. The current
trend of research is the investigation of medicines of plant origin
because of their affordability and accessibility with minimal side
effects (Calixto et al., 2001, 2003, 2004; Calixto, 2005).
The Piperaceae family consists of 14 genera and over 1950
species that are highly commercially, economically and medicinally
important. Piper is the largest genus in the family with 1000 species
(Mabberley, 1997); it is widely distributed in tropical and subtropi-
cal regions, and there are 260 species found in Brazil (Guimar~aes
and Giordano, 2004). Chemical studies performed on some of the
species have demonstrated that they contain diverse secondary
metabolites, including lignans, neolignans, terpenes, chalcones,
ﬂavones, alkaloids, amides and propenyl phenoles (Parmar et al.,
1997; Navickiene et al., 2000; Facundo and Morais, 2003; Bezerra
et al., 2008; Bokesch et al., 2011; Xie et al., 2011).
Some species of Piper have been shown to possess several
biological actions, such as immunomodulatory, anti-inﬂammatory,
antinociceptive, antipyretic, anti-platelet, antifungic, cytotoxic, anti-
tumor, gastroprotective, anxiolytic and antidepressive properties
(Majdalawieh and Carr, 2010; Sunila and Kuttan, 2004; Rodrigues
Silva et al., 2008; Xie et al., 2011; Yao et al., 2009; Rodrigues et al.,
2009; Sireeratawong et al., 2010; Koroishi et al., 2008; Quı´lez et al.,
2010; Morikawa et al., 2004; Zakaria et al., 2010; Cı´cero et al., 2007;
Bezerra et al., 2006; for review see Sarris et al., 2011).
Piper alyreanum C.DC, a member of the Piperaceae family, is a
small tree that is widely distributed in tropical and subtropical
regions, mostly in North and South America. Here in Brazil, it is
found in the North, mainly in the Amazon forest, and is popularly
known as ‘‘Jo~ao brandinho’’, ‘‘pimenta longa,’’ ‘‘pimenta longa da
mata,’’ ‘‘pimenta de cobra’’ and ‘‘pani-nixpu’’. Moreover, this plant
has been used as an immunomodulator, analgesic and antide-
pressant in folk medicine. Recently, Facundo and Morais, (2003)
described the isolation and characterization of b-sitosterol,
2-methoxy-4,5-methylenedioxypropi-ophenone and galangin
from the leaves from Piper alyreanum.
In addition, Facundo et al. (2007) demonstrated the presence
of b-pinene (14.4%), isocaryophyllene (17.5%) and b-caryophyl-
lene (18.6%) in the essential oils obtained from the leaves of P.
aleyreanum (EOPa). Taking into account the popular uses and
biological activities of the Piper genus, it is surprising that no
pharmacological study has been performed concerning the anti-
nociceptive, anti-inﬂammatory and gastroprotective actions of P.
aleyreanum. Here, we examined: (i) the chemical composition of
EOPa; (ii) the possible antinociceptive, anti-inﬂammatory and
gastroprotective effects of EOPa in standard rodent models of
pain, inﬂammation, and acute gastric lesions; and (iii) the
possible involvement of opioidergic systems and cytoprotectivefactors, such as gastric mucus and GSH levels, respectively, in the
antinociceptive and gastroprotective effects of EOPa.2. Materials and methods
2.1. Plant material
Piper aleyreanum C.DC was collected in September 2008 in the
southeastern Amazonian Forest, Porto Velho (Rondoˆnia State,
Brazil) and was classiﬁed by Dr. J. Gomes from the INPA herbar-
ium (Instituto Nacional de Pesquisa da Amazoˆnia). A voucher
specimen (no. 223303) was deposited in the INPA herbarium.2.2. Essential oil extraction and analysis
Essential oil was extracted with vapor dragging and water
distillation. The fresh aerial (leaves and stems) parts of Piper
aleyreanum (5.0 kg) were placed in a container, and a water vapor
current was passed through it under pressure. The volatile
products present in the aerial parts were dragged by the water
vapor, and the mixture was transported to a condenser where the
vapors returned to the liquid state and were collected in a
separator ﬂask. EOPa was dried over anhydrous sodium sulfate,
and its percentage content was calculated based on the plant
fresh weight, resulting in an oil yield of 1%. The oil analysis was
performed on a gas chromatography with mass spectrometry
detection (GC–MS, model 3800) and ion trap detector (MS, model
4000) (Varian, CA), with electron ionization-mass spectrometry
(EI-MS 70 eV). The analysis was developed in a VF1-MS capil-
lary column (Varian, CA), 30 m long, 0.25 mm thickness and
0.25 mm i.d., with helium at 1 ml/min as carrier gas Temperature
setup: injector at 250 1C, column-oven from 60 to 240 1C at 3 1C/
min (Santos et al., 2001), over 70 min. The quantitative analysis
was obtained by peak-area integration, using a Trace GC (Thermo-
Scientiﬁc), with ﬂame ionization detector (FID) operated under
similar conditions to those in GC–MS.
The retention index (RI) was calculated for all the volatile
constituents using an n-alkane homologous series, ranging from C8
to C30, using a linear temperature programmed equation (Van den
Dool and Kratz, 1963). Individual components were identiﬁed by
comparing the mass spectra and CG-retention data with those of
authentic compounds previously analyzed and stored in the database
from the National Institute of Standards and Technology (NIST). The
interpretation of RI values was assisted by the Terpenoids Library List
(http://massﬁnder.com/wiki/Terpenoids_Library_List).2.3. Animals
The experiments were conducted using adult male Swiss mice
(25–35 g) and male Wistar rats (200–250 g) that were housed at
2272 1C under a 12-h light/dark cycle (lights on at 06:00) with free
access to food and water. The animals were habituated to the
laboratory conditions for at least two hours before testing. The
experiments were performed between 09:00 and 16:00. Each animal
was used only once during the study and immediately after the test
they were sacriﬁced by CO2 asphyxiation. The experiments were
conducted in accordance with the ‘‘Principles of Laboratory Animal
Care’’ (NIH Publication 85-23, revised 1985) and approved by the
Ethics Committee for Animal Research of both the Federal University
of Santa Catarina (protocol number PP00467) and the Federal Uni-
versity of Parana (protocol number 446). The number of animals used
and the intensity of the noxious stimuli were the minimum necessary
to obtain reliable data.
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The procedure used was similar to a previously described
protocol (Santos and Calixto, 1997; Santos et al., 1999). The mice
received 20 ml of a 2.5% formalin solution (0.92% formaldehyde) in
saline via an intraplantar injection in the ventral surface of the
right hindpaw. The mice received EOPa (30–1000 mg/kg, p.o.) or
acetylsalicylic acid (400 mg/kg, p.o., used as positive control)
60 min before the formalin injection (Saragusti et al., 2012). The
control mice were treated with vehicle (10 ml/kg, p.o.). Following
the intraplantar injection of formalin, the mice were immediately
placed in a glass cylinder (20 cm diameter), and the time spent
licking the injected paw was recorded with a chronometer for
both the early neurogenic phase (0–5 min) and late inﬂammatory
phase (15–30 min) of this model. These values were considered
measures of nociception.
2.5. Involvement of the opioid system
To investigate the possible involvement of the opioid system
in the antinociceptive effect of EOPa, the mice were pretreated
with the nonselective opioid receptor naloxone (1 and 5 mg/kg,
i.p.) (Santos et al., 1999). After 20 min, the animals received an
injection of EOPa (100 mg/kg, p.o.), morphine (2.5 mg/kg, s.c.) or
vehicle (10 ml/kg, p.o.). The other groups were pretreated with
vehicle and received morphine, EOPa, or vehicle after 20 min.
After 60 and 30 min, they received a formalin (2.5%) injection, and
the time spent licking the injected paw was recorded for both the
early and late phases of the model.
2.6. Evaluation of locomotor activity
The open-ﬁeld test was used to exclude the possibility that the
antinociceptive action of EOPa could be related to non-speciﬁc
locomotor activity disturbances. Ambulatory behavior was assessed
in an open-ﬁeld test, as described previously (Rodrigues et al., 2002).
The apparatus consisted of a wooden box measuring 4060
50 cm. The arena ﬂoor was divided into 12 equal squares, and the
number of squares crossed with all paws was counted in a 6-min
session. The mice were treated with EOPa (100 or 300 mg/kg, p.o.) or
vehicle (10 ml/kg, p.o.) 60 min before the test.
2.7. Carrageenan-induced pleurisy
Pleurisy was induced in anaesthetized animals by an intrapleural
injection of carrageenan (1%) or a sterile saline solution (0.9% NaCl)
into the right pleural space through the chest skin (ﬁnal volume
0.1 ml) (Henriques et al., 1992; Saleh et al., 1996, 1997). On the day
of the experiments, the animals were challenged with Evans blue
dye solution (25 mg/kg, 0.2 ml, i.v.) to evaluate the degree of
exudation into the pleural space (Henriques et al., 1992; Saleh
et al., 1996). After 1 h, the animals received an injection of EOPa (1–
100 mg/kg, p.o.) or vehicle (10 ml/kg, p.o.). The positive control
group was pre-treated with indomethacin (5 mg/kg, i.p.) or dex-
amethasone (0.5 mg/kg, s.c.) 30 min before carrageenan injection
(Saleh et al., 1997). The animals were killed 4 h after the carragee-
nan injection, the pleural cavity was washed with 1 ml of sterile
saline solution plus heparin (20 UI/ml), and the ﬂuid in the pleural
space was collected with automatic pipettes. Total leukocyte counts
were performed using pleural ﬂuid diluted with Tu¨rk solution (1:20)
placed in a Neubauer chamber and assessed with an optical
microscope. Cellular smears were prepared with another aliquot of
pleural washing and stained with May–Gru¨nwald–Giemsa for the
differential analysis, which was performed under an immersion
objective. A sample of ﬂuid (300 ml) collected from the pleural space
was stored in the freezer (20 1C) and later used to determine theconcentration of Evans blue dye. This was performed by obtaining
the absorbance values at 600 nm with a spectrophotometer and
comparing them to the standard curve of Evans blue dye in the
range of 1–500 mg/ml.
2.8. Induction of acute gastric lesions
The possible gastroprotective effects of EOPa were investigated
on acute ethanol-induced lesions in rats (Robert et al., 1979). The
rats were fasted overnight (18 h) prior to the experiment but
were allowed free access to water. Animals were treated with
vehicle (C: water or saline plus 0.5% Tween 80, 10 ml/kg, p.o. or
i.p.), EOPa (10, 30 or 100 mg/kg, p.o.; or 10 mg/kg, i.p.) or
omeprazole (40 mg/kg, p.o. or i.p., used as positive control),
60 min (p.o.) or 30 min (i.p.) before the oral administration of
ethanol (0.5 ml/200 g)(Baggio et al., 2007). One hour later, the
animals were sacriﬁced, the stomachs were removed, and the
lesioned gastric area (mm2) was measured using the program
Image Tool 3.0s, as previously described (Potrich et al., 2010).
Gastric lesion extension was measured as the total injured area
(length in mmwidth in mm), as previously described (Baggio
et al., 2007). Finally, the gastric tissues were weighed and used to
determine the mucus and glutathione (GSH) content.
2.9. Determination of gastric mucus
The gastric tissues were immediately transferred to 0.1% alcian
blue solution prepared in 0.16 mM sucrose and 50 mM sodium
acetate (pH 5.0) and stained for 2 h at room temperature. Next,
the gastric mucosa was rinsed twice with 250 mM sucrose
solution for 15 and 45 min, and the dye complexed with the
gastric mucus was extracted with 500 mM magnesium chloride
solution, which was intermittently shaken for 1 min every 30 min
for 2 h. The extract was then mixed with an equal volume of
diethyl ether and centrifuged at 1450g for 10 min. Absorbance
was read at 598 nm. The amount of mucus was calculated using
standard curves of alcian blue (6.25–100.0 mg), and the results
were expressed in mg of Alcian Blue/g tissue (Corne et al., 1974).
2.10. Determination of glutathione (GSH) content
Ulcerated stomach tissue samples were homogenized in
200 mM potassium phosphate buffer (pH 6.5, 4 1C) to determine
the GSH levels, according to the method of Sedlak and Lindsay
(1968). Aliquots of the tissue homogenate were mixed with 12.5%
trichloroacetic acid, vortexed for 10 min and centrifuged for
15 min at 9000g. The supernatant was reserved, and Tris buffer
(0.4 M, pH 8.9) and 5,50-dithiobis-2-nitrobenzoic acid (DTNB,
0.01 M) were added to it. The absorbance of the supernatant
was measured by spectrophotometry at 415 nm. The individual
values were compared to a standard curve of GSH, and the results
were expressed as mg of GSH/g of tissue.
2.11. Drugs
The following substances were used: formalin, morphine
hydrochloride and Tween 80 (Merck, Darmstadt, Germany);
alcian blue, dexamethasone, indomethacin, acetylsalicylic acid,
omeprazole and naloxone hydrochloride (Sigma Chemical Co., St.
Louis, USA). All the drugs were dissolved in saline solution (0.9%
NaCl) with the exception of essential oil and acetylsalicylic acid,
which were dissolved in saline plus Tween 80, and indomethacin,
which was dissolved in saline with 5% DMSO. The ﬁnal concen-
tration of Tween 80 did not exceed 5% and did not cause any
effect per se. All the control animals received the vehicle used to
dissolve the essential oil.
Table 1
Chemical composicion of the Piper aleyreanum essential oil.
Peak Compound a% bRt cRIcalc dRIlit Identiﬁcation
(eEI-MS/fNIST, RI)
1 Tyranton 2.0 3.286 901.0 – EI-MS, NIST
2 Allylcyclohexane 0.3 4.243 926.4 – EI-MS, NIST
3 Camphene 5.2 5.309 954.7 950 EI-MS, NIST, RI
4 n.i. 0.6 6.208 978.5 978 EI-MS, NIST, RI
5 b-pinene 9.0 6.331 981.8 978 EI-MS, NIST, RI
6 o-cymene 1.6 7.55 1014.7 1013 EI-MS, NIST, RI
7 Limonene 0.8 7.822 1022.3 1025 EI-MS, NIST, RI
8 Linalool 0.8 10.102 1085.3 1086 EI-MS, NIST, RI
9 n.i. 1.4 10.324 1091.4 – –
10 a-campholenal 0.8 10.779 1104.0 1105 EI-MS, NIST, RI
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The results are presented as the mean7the standard error of
mean (S.E.M.), except for the ID50 values (i.e., the dose of EOPa
necessary to reduce the nociceptive response by 50% relative to
the control value), which are reported as geometric means
accompanied by their respective 95% conﬁdence limits. The
ID50 values were determined by nonlinear regression from
individual experiments using linear regression with GraphPad
software (GraphPad software, San Diego, CA, USA). Statistical
signiﬁcance was determined with an analysis of variance
(ANOVA) followed by Newman–Keuls tests. P-values less than
0.05 (Po0.05) were considered signiﬁcant.11 Norinone 0.7 10.96 1109.0 – EI-MS, NIST
12 (E)-Sabinol 0.4 11.534 1124.9 1120 EI-MS, NIST, RI
13 (Z)-Verbenol 1.0 11.793 1132.0 1132 EI-MS, NIST, RI
14 Pinocarvone 3.1 12.088 1140.2 1137 EI-MS, NIST, RI
15 Myrtenal 4.2 13.303 1173.8 1172 EI-MS, NIST, RI
16 Verbenone 3.3 13.808 1187.8 1183 EI-MS, NIST, RI
17 Linalyl acetate 2.1 16.147 1246.9 1239 EI-MS, NIST, RI
18 d-elemene 0.3 19.719 1335.4 1340 EI-MS, NIST, RI
19 a-cubebene 1.8 20.255 1348.7 1355 EI-MS, NIST, RI
20 n.i. 0.5 20.993 1366.9 – –
21 a-copaene 1.6 21.295 1374.4 1379 EI-MS, NIST, RI
22 b-bourbonene 1.2 21.578 1381.4 1386 EI-MS, NIST, RI
23 b-cubebene 1.1 21.778 1386.4 1390 EI-MS, NIST, RI
24 b-elemene 4.7 21.83 1387.6 1389 EI-MS, NIST, RI
25 (E)-b-Caryophyllene 0.9 22.898 1415.0 1421 EI-MS, NIST, RI
26 n.i. 0.8 23.289 1425.3 – –
27 n.i. 0.5 23.508 1431.1 – –
28 g-muurolene 1.4 25.077 1472.4 1474 EI-MS, NIST, RI
29 b-selinene 0.5 25.418 1481.4 1486 EI-MS, NIST, RI
30 d-selinene 1.4 25.779 1490.9 1496 EI-MS, NIST, RI
31 a-muurolene 0.8 26.021 1497.3 1496 EI-MS, NIST, RI
32 g-cadinene 2.4 26.471 1509.2 1507 EI-MS, NIST, RI
33 Elemol 1.5 27.676 1540.9 1541 EI-MS, NIST, RI
34 (E)-nerolidol 1.2 28.23 1555.5 1553 EI-MS, NIST, RI
35 Spathulenol 6.7 28.694 1567.8 1572 EI-MS, NIST, RI
36 Caryophyllene oxide 11.5 28.801 1570.6 1578 EI-MS, NIST, RI
37 Viridiﬂorol 2.6 29.285 1583.3 1592 EI-MS, NIST, RI
38 n.i. 2.6 29.719 1594.8 – –
39 6-epi-cubenol 1.1 30.11 1605.6 1602 EI-MS, NIST, RI
40 Isospathulenol 1.2 30.563 1618.8 1625 EI-MS, NIST, RI
41 a-cadinol 2.5 31.438 1644.2 1643 EI-MS, NIST, RI
42 n.i. 1.5 32.716 1681.4 – –
43 n.i. 1.7 34.936 1745.9 – –
44 n.i. 4.1 35.147 1752.0 – –
45 n.i. 4.6 37.068 1808.7 – –
n.i.—not identiﬁed.
a %—relative abundances from the peak area integration.
b Rt—retention time (min) from a linear temperature program.
c RIcalc—retention index calculated for each compound.
d RIlit—retention index obtained from literature (http://massﬁnder.com/wiki/
Terpenoids_Library_List).
e EI-MS—electron ionization mass spectrometry.
f NIST—data bank from National Institute of Standards and Technology.3. Results
3.1. Essential oil extraction and analysis
The chemical analysis of the EOPa sample used in the present
investigations identiﬁed 35 compounds, representing 81.7% of the
total oil content (Table 1). Caryophyllene oxide (11.5%), b-pinene
(9%), spathulenol (6.7%), camphene (5.2%), b-elemene (4.7%),
myrtenal (4.2%), verbenone (3.3%) and pinocarvone (3.1%) were
found to be major constituents (Table 1).
3.2. Formalin-induced nociception
The results depicted in Fig. 1A and B show that EOPa (30–
1000 mg/kg, p.o.) signiﬁcantly inhibited both the neurogenic (0–
5 min) and inﬂammatory (15–30 min) phases of formalin-induced
licking. However, its antinociceptive effects were signiﬁcantly
more pronounced against the second phase of this pain model.
The calculated mean ID50 value (and its respective 95% con-
ﬁdence limits) for these effects were: 281.2 (196.3–402.7) and
70.5 (53.9–92.0) mg/kg, and the inhibitions observed were
7573% and 9971% at a dose of 1000 mg/kg, for the ﬁrst and
second phases, respectively. In contrast, the NSAID acetylsalicylic
acid (400 mg/kg, p.o.), given 60 min before the assay, only
signiﬁcantly reduced the inﬂammatory (6677%) phase of for-
malin-induced pain (Fig. 1A and B).
3.3. Opioid system involvement
Pre-treatment with the non-selective opioid receptor antago-
nist naloxone (1 or 5 mg/kg, i.p.) 20 min beforehand, did not
reverse the antinociception caused by EOPa (100 mg/kg, p.o.), but
it completely reversed the antinociception caused by morphine
(2.5 mg/kg, s.c.) during formalin-induced pain (Fig. 2A and B).
3.4. Locomotor activity evaluation
EOPa treatment (100 or 300 mg/kg, p.o.) did not alter mouse
ambulation in the open-ﬁeld test. The crossing numbers after
administration were 80.173.0, 89.0710.7 and 52.0715.4 for
the control group and the groups receiving 100 or 300 mg/kg of
EOPa, respectively.
3.5. Carrageenan-induced pleural acute inﬂammation
The intrapleural injection of carrageenan produced acute inﬂam-
mation characterized by plasma leakage and considerable leukocyte
migration, represented by neutrophils and mononuclear cells
(Fig. 3A–D). Treatment with EOPa (1–100 mg/kg, p.o.) given 1 h
prior to carrageenan signiﬁcantly decreased the total cell count and
the number of neutrophils and mononuclear cells with mean ID50values of 53.6 (19.9–143.9), 21.7 (10.2–46.0) and 43.5 (16.0–
118.0) mg/kg and inhibitions of 54713%, 66710% and 6078%,
respectively (Fig. 3A, C, and D). The same doses of EOPa also reduced
exudation (4579% at dose of 3 mg/kg, Fig. 3B). Pre-treatment with
dexamethasone (0.5 mg/kg, s.c.) and indomethacin (5 mg/kg, i.p.)
30 min before the carrageenan injection reduced the total leukocyte
count by 9575% and 9272%, the differential neutrophil count by
9773% and 9872%, and pleural exudation by 8973% and 9773%,
respectively (Fig. 3A–D).
3.6. Effects on gastric injury
EOPa treatment (1–30 mg/kg, p.o.) caused a dose-dependent
reduction in ethanol-induced gastric lesions, decreasing the ulcer
area mainly at doses of 10 and 30 mg/kg (Fig. 4A), with a mean
Fig. 1. Effects of Piper aleyreanum essential oil (30–1000 mg/kg, p.o.) or acetylsalicylic acid (ASA, 400 mg/kg, p.o.) on the ﬁrst (panel A) and second phase (panel B) of
formalin-induced licking in mice. Each column represents the mean7S.E.M. (n¼6–10). Control values (C) indicate vehicle (saline and Tween 80, 10 ml/kg) administration,
and the asterisks denote signiﬁcance levels when compared with the control group; *Po0.05, ***Po0.001.
Fig. 2. Effect of pre-treatment of animals with naloxone (1 or 5 mg/kg, i.p.) on the antinociceptive proﬁles of Piper aleyreanum essential oil (100 mg/kg, p.o.) or morphine
(2.5 mg/kg, s.c.) on the ﬁrst (panel A) and second phase (panel B) of formalin-induced licking in mice. Each column represents the mean7S.E.M. (n¼6–10). Asterisks
denote signiﬁcance levels compared with control groups (vehicle groups), ##Po0.01. *Po0.05 and **Po0.01 compared with agonists (Piper aleyreanum or morphine
plus vehicle).
Fig. 3. Effects of Piper aleyreanum essential oil (1–100 mg/kg, p.o.), dexamethasone (DEX, 0.5 mg/kg, s.c.) or indomethacin (IND, 5 mg/kg, i.p.) on total leukocyte count
(panel A), pleural leakage (panel B), neutrophils (panel C) and mononuclear cell count (panel D) in carrageenan-induced pleurisy in mice. Each column represents the
mean7S.E.M. (n¼4–8). N represents the group injected with 0.9% saline; (C) indicates the group treated with carrageenan and the vehicle used to dilute the essential oil.
The difference between the groups was determined by an ANOVA followed by Newman–Keuls multiple comparison test. *Po0.05, **Po0.01, ***Po0.001 when compared
with carrageenan-treated group; #Po0.05, ##Po0.001 when compared to saline group (S).
D.K.S. Lima et al. / Journal of Ethnopharmacology 142 (2012) 274–282278ID50 value of 1.7 (0.9–3.1) mg/kg (injured control group
value¼26.472.9 mm2) and an inhibition of 8774% at 10 mg/
kg. The positive control omeprazole (40 mg/kg, p.o.) reduced
ethanol-induced gastric lesions by 9272%.Ethanol administration decreased gastric mucus and GSH levels
by 64.973.9% and 35.573.0%, respectively, when compared to the
non-lesioned group (N: 61.574.1 mg alcian blue/g of tissue
and 267.7710.9 mg of GSH/g of tissue). EOPa administration
Fig. 4. Effects of Piper aleyreanum essential oil (1–30 mg/kg, p.o., panel A, B, and C or 10 mg/kg, i.p., panels a–c) on ethanol-induced gastric lesions (panel A and a) and
glutathione (panel B and b) and gastric mucus (panel C and c) levels in rats. Each column represents the mean7S.E.M. (n¼6–10). Control values (C) indicate the
administration of vehicle (saline and Tween 80, 10 ml/kg) plus ethanol. N represents the group injected with vehicle; O indicates the group treated with omeprazole
(40 mg/kg). Differences between the groups were determined by an ANOVA followed by Newman–Keuls multiple comparison test. *Po0.05, **Po0.01, ***Po0.001 when
compared with the ethanol-treated group; #Po0.05, ##Po0.001 when compared to the vehicle group (N).
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to 50.375.6 mg alcian blue/g of tissue and GSH from 255.8714.6
to 297.7724.4 mg of GSH/g of tissue when compared to the injured
control (C: 21.472.4 mg alcian blue/g of tissue and 172.778.0 mg
of GSH/g of tissue) (Fig. 4B and C). Furthermore, omeprazole
(40 mg/kg, p.o.) signiﬁcantly increased the gastric mucus and
GSH levels relative to the injured control (Fig. 4B and C).
Similarly, the i.p. administration of EOPa (10 mg/kg) and
omeprazole (40 mg/kg, i.p.) reduced (by 44.8712.8% and
78.074.2%, respectively) ethanol-induced gastric lesions and
increased the gastric wall mucus to 34.271.5 and 30.472.7 mg
alcian blue/g of tissue, respectively, when compared to lesioned
group (C: 18.470.34 mg alcian blue/g of tissue) (Fig. 4a and c).
Moreover, treatment with EOPa (10 mg/kg, i.p.) and omeprazole
(40 mg/kg, i.p.) also increased the GSH levels to 215.3717.8 and
213.8720.3 mg of GSH/g of tissue, respectively, compared to the
injured control (138.5715.5 mg of GSH/g of tissue) (Fig. 4b).4. Discussion
Previous chemical reports of the essential oil obtained from
Piper aleyreanum leaves collected from the southern Amazon
forest in Porto Velho (Rondoˆnia State), Brazil, revealed that the
major components were sesquiterpenes b-caryophyllene (18.6%)
and isocaryophyllene (17.5%) and monoterpene b-pinene (14.4%)
(Facundo et al., 2007). Here, we used GC/MS to identify 35
compounds in EOPa, which accounts for 81.7% of the total oil
content. The main components were sesquiterpenes caryophyl-
lene oxide (11.5%), spathulenol (6.7%), b-elemene (4.7%), mono-
terpenes b-pinene (9%), camphene (5.2%), myrtenal (4.2%),
verbenone (3.3%) and pinocarvone (3.1%). Interestingly, the diver-
gent data regarding the previous component characterization and
our results might be related to the age of the plant; the part
collected and environmental factors, resulting in a different
chemical composition of EOPa (Maciel et al., 2000). However,
further studies are needed to investigate this hypothesis.As mentioned earlier, the plants of the genus Piper have a
great diversity of secondary metabolites and are known for their
immunomodulatory, anti-inﬂammatory, antinociceptive, anti-
pyretic, anti-platelet, antifungic, cytotoxic, antitumor, gastropro-
tective, anxiolytic and antidepressive properties (Majdalawieh
and Carr, 2010; Sunila and Kuttan, 2004; Ganguly et al., 2007;
Chiou et al., 2003; Rodrigues Silva et al., 2008; Xie et al.,
2011; Yao et al., 2009; Rodrigues et al., 2009; Sireeratawong et al.,
2010; Koroishi et al., 2008; Marques et al., 2007; Quı´lez et al., 2010;
Morikawa et al., 2004; Zakaria et al., 2010; Cı´cero et al., 2007;
Navickiene et al., 2000; Bezerra et al., 2006; for review see Sarris
et al., 2011). In addition, the literature suggests that the essential oil
obtained from some species of Piper also have various biological
activities, such as anti-parasitic, insecticidal, larvicidal, antimicro-
bial, antifungal and antioxidant properties (Marques et al., 2010;
Misni et al., 2011; Salleh et al., 2011; da Silva et al., 2010, 2011;
Monzote et al., 2010; Magalh~aes et al., 2012).
Furthermore, no reports were found in the literature regarding
the biological actions of Piper aleyreanum, and although some
pharmacological actions of the essential oil of Piper species have
been reported, no speciﬁc antinociceptive, anti-inﬂammatory or
gastroprotective actions of EOPa have been reported in the
literature. The present results show for the ﬁrst time that oral
EOPa exerts potent antinociceptive and anti-inﬂammatory effects
against nociception, vascular leakage and leukocyte migration in
two different pain and inﬂammation models. Interestingly, both
administration routes (oral and intraperitoneal) of EOPa increased
the protective factors, such as mucus and GSH, and protected the
gastric mucosa against ethanol-induced lesions.
In the present study, we demonstrated that EOPa has a signiﬁ-
cant antinociceptive effect on formalin-induced pain in mice, a
classical chemical model of nociception. The results reported here
indicate that the oral administration of essential oil produced
marked and dose-related antinociception against both neurogenic
(ﬁrst phase) and inﬂammatory (late phase) pain responses caused
by formalin injection in mice. Also, the antinociception caused by
EOPa was unlikely to be secondary to its non-speciﬁc muscle
relaxant, speciﬁc and/or non-speciﬁc depressant central effects as
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side effects in the open-ﬁeld test.
The formalin test is a satisfactory and comprehensive model
for evaluating the antinociceptive activity of drugs. The intra-
plantar injection of formalin activates nociceptive nerve terminals
and produces neurogenic pain, whereas inﬂammatory pain is
mediated by a combination of peripheral input and spinal cord
sensitization (Hunskaar and Hole, 1987; Tjolsen et al., 1992).
It has been demonstrated that the intraplantar injection of formalin
in rodents increases spinal levels of excitatory amino acids, PGE2,
nitric oxide, tachykinin, kinins, among other peptides (Tjolsen
et al., 1992; Malmberg and Yaksh, 1992; Santos and Calixto, 1997;
Santos et al., 1998). Experimental data indicate that formalin
predominantly evokes activity in C-ﬁbers (Tjolsen et al., 1992),
although Ad-ﬁbers are thought to be responsible for fast nocicep-
tive transmission in the ﬁrst phase of the pain response (Julius
and Basbaum, 2001).
It is notable that the nociception produced by formalin (ﬁrst
phase) is quite resistant to the majority of NSAIDs, such as
acetylsalicylic acid (results presented here), indomethacin, para-
cetamol, and diclofenac. However, these drugs can dose-depen-
dently attenuate the second phase of formalin-induced licking
(Hunskaar and Hole, 1987; Malmberg and Yaksh, 1992; Santos
et al., 1998). Moreover, it has also been reported that morphine,
some tachykinin receptor antagonists, non-selective excitatory
amino acid antagonists and both B1 and B2 bradykinin receptor
antagonists are able to inhibit both phases of the formalin test (De
Campos et al., 1996; Santos and Calixto, 1997). The present study
shows that the opioid system is unlikely to be involved in the
antinociceptive action of EOPa. This is inferred by the fact that the
pre-treatment of animals with naloxone, a nonselective opioid
receptor antagonist, completely inhibited the antinociceptive
effect of morphine but not the action of EOPa in the formalin
model. Moreover, our data showed that EOPa inhibited both
phases of formalin test but was more effective against the
inﬂammatory (second phase) pain; this data led us to investigate
its anti-inﬂammatory effect.
Treatment with EOPa resulted in a pronounced anti-inﬂammatory
effect against acute carrageenan-induced pleurisy. It has been shown
that the carrageenan-induced mouse pleural inﬂammatory response
elicits the release of chemical mediators such as histamine, bradyki-
nin, substance P, and prostaglandins, which is followed by exudation
and leukocyte inﬁltration into the inﬂammatory site; this peaks at 4 h
after pleurisy induction (Menegazzi et al., 2008; Tomlinson et al.,
1994; Saleh et al., 1996, 1997). This acute inﬂammatory response is
usually inhibited by NSAIDs, such as indomethacin or corticoids such
as dexamethasone, and these effects have been attributed to the
inhibition of mediator release and the tissue expression of inducible
cyclooxygenase (COX-2) (Nantel et al., 1999).
Here, we conﬁrm these observations and demonstrate that
EOPa treatment reduced the main features of acute inﬂammation,
including exudation and leukocyte number, characterized mainly
by a reduction in neutrophil differential cell count in the pleural
cavity. These ﬁndings suggest that EOPa has a critical role in
controlling acute inﬂammatory events. Singh et al. (2008)
reported that the chloroform extract of Piper longum inhibited
neutrophil adherence to the endothelial monolayer by inhibiting
the TNF-a-induced expression of intercellular adhesion molecule-
1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1) and
E-selectin, and this effect is probably mediated by NFkB inhibition
in endothelial cells. Recently, Amran et al. (2011) demonstrated
that the aqueous extract of Piper sarmentosum signiﬁcantly
reduced the levels of VCAM-1, ICAM-1 and C-reactive protein
(CRP) in experimental rabbits fed a 1% cholesterol diet, suggesting
that this plant may have a beneﬁcial effect in preventing athero-
sclerosis. Future studies are needed to investigate the possibleeffect of EOPa on these inﬂammatory markers that enhance both
acute and chronic inﬂammation.
NSAIDs (i.e., indomethacin or acetylsalicylic acid) are known
to induce gastric damage due to nonspeciﬁc inhibition of
cyclooxygenase-1 (COX-1) and COX-2, and this dual inhibition
may lead to gastrointestinal ulceration and bleeding (Wallace
et al., 2000; Wallace, 2008). We evaluated whether EOPa treat-
ment could protect the gastric mucosa. Notably, EOPa exerts
gastroprotective activity and prevents the formation of acute
hemorrhagic erosion caused by oral ethanol administration.
Ethanol is a well-known necrotizing agent that destroys the
mucus barrier, increases vascular permeability, and decreases
the number of non-protein sulfhydryl groups (NP-SH) of the
gastric mucosa (Repetto and Llesuy, 2002; Siegmund, 2003),
which leads to hemorrhagic gastric erosion. Gastric mucus is
one of the main defensive elements against aggressive agents. It is
continuously secreted by epithelial cells and serves as a physical
barrier over the mucosa (Bi and Kaunitz, 2003). Our results clearly
show that compared to the NSAIDs indomethacin and acetylsa-
licylic acid, which are broadly used in the clinical management of
inﬂammatory diseases, EOPa does not have adverse gastrointest-
inal effects. EOPa treatment exerts an anti-ulcer effect on ethanol
lesions. The cytoprotective mechanism appears to be related to
increased levels of mucus and anti-oxidant factor such as GSH.
In this study, the extract was given by two different routes to
evaluate whether the observed effect was due to an adherent
property of the extract on the gastric mucosa, resulting in the
formation of a protective barrier against the necrotizing effects of
ethanol. EOPa given by the intraperitoneal route showed the same
effects on GSH levels and mucus production, suggesting that the
observed results were not due to EOPa’s adherence to the
gastric wall.
EOPa is chemically composed of terpenes, such as sesquiter-
penes and monoterpenes, and their biological activity could be
attributed to the high concentrations of caryophyllene oxide
(11.5%) and b-pinene (9%). However, we cannot conﬁrm that
the antinociceptive, anti-inﬂammatory and gastric antiulcer activ-
ities of EOPa are attributable to the single or synergistic action of
these main components or even other minor constituents present
in the oil.
In conclusion, the present study demonstrates that EOPa
exerts dose-dependent antinociceptive action against formalin-
induced nociception, without affecting locomotor activity. In
addition, the antinociceptive action of EOPa is not dependent on
the opioid system. EOPa treatment exerted an important anti-
inﬂammatory action and interesting gastroprotective effects
related to the maintenance of protective factors, such as mucus
production and GSH. This study provides a pharmacological basis
for EOPa use in folk medicine and shows that this plant has
potential for the development of safe phytomedicines with anti-
nociceptive and anti-inﬂammatory effects and gastroprotective
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